Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors while in the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements review located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://johno439oka3.wikipresses.com/user